Edition:
United Kingdom

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

12.62USD
13 Dec 2017
Change (% chg)

$0.15 (+1.20%)
Prev Close
$12.47
Open
$12.42
Day's High
$12.72
Day's Low
$12.15
Volume
10,928
Avg. Vol
9,124
52-wk High
$18.93
52-wk Low
$6.40

Chart for

About

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The... (more)

Overall

Beta: --
Market Cap(Mil.): $208.23
Shares Outstanding(Mil.): 12.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

* Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

15 Nov 2017

BRIEF-Spring Bank Pharmaceuticals may offer and sell shares of up to $50 mln common stock

* Spring Bank Pharmaceuticals Inc files to say may offer and sell shares of up to $50 million of common stock - SEC filing Source text: (http://bit.ly/2wpauAR) Further company coverage:

18 Aug 2017

BRIEF-BVF Partners reports 5.1 pct passive stake in Spring Bank Pharmaceuticals as of Aug. 3

* BVF Partners L.P reports 5.1 percent passive stake in spring bank pharmaceuticals inc as of august 3, 2017 - SEC filing‍​ Source text (http://bit.ly/2vWRyKp) Further company coverage:

11 Aug 2017

BRIEF-Spring Bank Pharmaceuticals posts Q2 loss per share $0.93

* Spring Bank Pharmaceuticals provides corporate update and reports second quarter 2017 financial and operational results

31 Jul 2017

BRIEF-Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200​

* Spring Bank Pharmaceuticals Inc - ‍announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining SB 9200​

10 Jul 2017

BRIEF-Spring Bank Pharma prices $37.5 mln public offering of common stock

* Spring bank pharmaceuticals prices $37.5 million public offering of common stock

22 Jun 2017

BRIEF-Spring Bank Pharma announces proposed public offering of common stock

* Spring Bank Pharmaceuticals announces proposed public offering of common stock

21 Jun 2017

Earnings vs. Estimates